Clinigen announces executive appointments to drive growth and investor value
Ella Day | May 1, 2025 | Appointment | Business Services, Pharmaceutical Consultancy Services | Clinigen, Keith Bryne, Nihad Hasagic, Pharma services, Pharmacy, appointment
Clinigen, the global pharmaceutical services group, has announced key leadership changes to accelerate its growth and strengthen its position in the expanding biopharma services market.
Nihad Hasagic (pictured left) has been appointed senior vice president (SVP) of Clinigen Lifecycle Services (CLS), reporting directly to CEO Jerome Charton. CLS supports pharmaceutical and biotech clients across the entire drug life cycle and will now expand its offering to include pharmacovigilance, regulatory affairs and medical information. Positioned within a global market forecast to reach be $1.21bn by 2034, CLS is set to unlock new value through scalable, high-impact services.
Hasagic, previously SVP of Strategic Initiatives, played a key role in launching CLS and shaping its commercial strategy. He also brings over 20 years of industry experience in the healthcare, life sciences and specialty chemicals industries.
“There is no one better placed than Nihad to lead CLS,” said Charton. “His leadership will be vital in driving value for clients, investors and patients.”
Also, Keith Byrne (pictured right), group head of corporate development, will now report directly to the CEO. An experienced professional in healthcare mergers and acquisitions, Byrne will support Clinigen’s growth agenda through targeted acquisitions.
These changes are effective immediately and form part of a broader strategy to enhance investor returns while delivering improved patient access to critical medicines.
Ella Day
1/5/25
Related Content
Digital Control Room, a major pharma provider, wins King’s Award for Enterprise
Buckingham Palace has announced that Digital Control Room, a software platform that monitors companies’ online …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
